Anticoagulation Timing in Acute Stroke With Atrial Fibrillation According to Chronic Kidney Disease: The OPTIMAS Trial
Philip S. Nash(National Hospital for Neurology and Neurosurgery), Lauren Binnie, Kamy Thavanesan(Bournemouth University), Robert Fenner(MRC Clinical Trials Unit at UCL), Aneet Gill(MRC Clinical Trials Unit at UCL), Daniel Esteban, Mark White(Beatson West of Scotland Cancer Centre), Emilia Caverly(MRC Clinical Trials Unit at UCL), Louise Mallon, Nick Freemantle(MRC Clinical Trials Unit at UCL), Caroline J Doré(MRC Clinical Trials Unit at UCL), Liz Arram(King's College London), Gregory Y.H. Lip(Medical University of Białystok), Marie Evans(Karolinska University Hospital), Maryam Balogun(National Hospital for Neurology and Neurosurgery), Youssif Abousleiman, Kate Bennett(MRC Clinical Trials Unit at UCL), Brian Clarke(MedStar Washington Hospital Center), Ekaterina Bordea(MRC Clinical Trials Unit at UCL), L. Broad, R. Price, Nikola Sprigg(Nottingham University Hospitals NHS Trust), Rachael Hunter(MRC Clinical Trials Unit at UCL), Macey L. Murray(MRC Clinical Trials Unit at UCL), Stefan T. Engelter(University Hospital of Basel), Gary A. Ford(University of Oxford), Bo Norrving(Lund University), David C. Wheeler(University College London), Norin Ahmed(MRC Clinical Trials Unit at UCL), Hannah Cohen(University College London Hospitals NHS Foundation Trust), Lucy Knibbs, Jonathan G. Best(University College London Hospitals NHS Foundation Trust), Hakim‐Moulay Dehbi(MRC Clinical Trials Unit at UCL), Tishok Vanniyasingam(MRC Clinical Trials Unit at UCL), Benjamin Jelley, Martin James(Royal Devon and Exeter Hospital), David J. Werring(Queen Mary University of London), Marisa Chau(MRC Clinical Trials Unit at UCL), Liqun Zhang(Capital University), Albert V. Smith(University of Iceland), Hannah Sims(MRC Clinical Trials Unit at UCL), Mairead Cullen(MRC Clinical Trials Unit at UCL), S. Hewson, L. Griebel, Sue Massingham(King's College London), Tamara Hughes, Iwona Mazurczak(MRC Clinical Trials Unit at UCL), Amalia Ndoutoumou(MRC Clinical Trials Unit at UCL)
Cited by 2
Related Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease
|Nature Genetics|2013|4.7k
A second generation human haplotype map of over 3.1 million SNPs
|Nature|2007|4.6k